These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33624833)

  • 1. QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small-Molecule New Drug Applications Approved During 2011-2019.
    Cohen-Rabbie S; Berges AC; Rekić D; Parkinson J; Dota C; Tomkinson HK
    J Clin Pharmacol; 2021 Aug; 61(8):1106-1117. PubMed ID: 33624833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do Studies Evaluating QT/QTc Interval Prolongation with Dietary Supplements Meet FDA Standards: A Systematic Review.
    Nguyen TA; Kurian A; Leong J; Patel UM; Shah SA
    J Diet Suppl; 2017 Jul; 14(4):467-477. PubMed ID: 27937000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents.
    Sarapa N; Britto MR
    Expert Opin Drug Saf; 2008 May; 7(3):305-18. PubMed ID: 18462188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
    Shah RR
    Drug Saf; 2005; 28(11):1009-28. PubMed ID: 16231954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
    Vargas HM; Rolf MG; Wisialowski TA; Achanzar W; Bahinski A; Bass A; Benson CT; Chaudhary KW; Couvreur N; Dota C; Engwall MJ; Michael Foley C; Gallacher D; Greiter-Wilke A; Guillon JM; Guth B; Himmel HM; Hegele-Hartung C; Ito M; Jenkinson S; Chiba K; Lagrutta A; Levesque P; Martel E; Okai Y; Peri R; Pointon A; Qu Y; Teisman A; Traebert M; Yoshinaga T; Gintant GA; Leishman DJ; Valentin JP
    Clin Pharmacol Ther; 2021 Feb; 109(2):310-318. PubMed ID: 32866317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs, QT interval prolongation and ICH E14: the need to get it right.
    Shah RR
    Drug Saf; 2005; 28(2):115-25. PubMed ID: 15691222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical issues including design and sample size calculation in thorough QT/QTc studies.
    Zhang J; Machado SG
    J Biopharm Stat; 2008; 18(3):451-67. PubMed ID: 18470755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance characteristics for some typical QT study designs under the ICH E-14 guidance.
    Hutmacher MM; Chapel S; Agin MA; Fleishaker JC; Lalonde RL
    J Clin Pharmacol; 2008 Feb; 48(2):215-24. PubMed ID: 18199896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly automated QT measurement techniques in 7 thorough QT studies implemented under ICH E14 guidelines.
    Couderc JP; Garnett C; Li M; Handzel R; McNitt S; Xia X; Polonsky S; Zareba W
    Ann Noninvasive Electrocardiol; 2011 Jan; 16(1):13-24. PubMed ID: 21251129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Safety Research Consortium: can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward.
    Darpo B; Garnett C; Benson CT; Keirns J; Leishman D; Malik M; Mehrotra N; Prasad K; Riley S; Rodriguez I; Sager P; Sarapa N; Wallis R
    Am Heart J; 2014 Sep; 168(3):262-72. PubMed ID: 25173536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The New S7B/E14 Question and Answer Draft Guidance for Industry: Contents and Commentary.
    Darpo B; Ferber G
    J Clin Pharmacol; 2021 Oct; 61(10):1261-1273. PubMed ID: 33896027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.
    Darpo B
    Br J Pharmacol; 2010 Jan; 159(1):49-57. PubMed ID: 19922536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecularly targeted oncology therapeutics and prolongation of the QT interval.
    Strevel EL; Ing DJ; Siu LL
    J Clin Oncol; 2007 Aug; 25(22):3362-71. PubMed ID: 17664484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assay sensitivity in "Hybrid thorough QT/QTc (TQT)" study.
    Huang DP; Chen J; Dang Q; Tsong Y
    J Biopharm Stat; 2019; 29(2):378-384. PubMed ID: 30346877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.
    Salvi V; Karnad DR; Panicker GK; Kothari S
    Br J Pharmacol; 2010 Jan; 159(1):34-48. PubMed ID: 19775279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies.
    Shah RR; Morganroth J
    Br J Clin Pharmacol; 2013 Apr; 75(4):959-65. PubMed ID: 22905923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of baseline measurement on the change from baseline in QTc intervals.
    Tian H; Natarajan J
    J Biopharm Stat; 2008; 18(3):542-52. PubMed ID: 18470762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.